Nanjing Pharmaceutical Company Limited’s Net Profit Rose 31.2% in First Three Quarters of 2022

Nanjing Pharmaceutical Company Limited (南京医药股份有限公司) (600713.SH) reported a net profit of 555.6 million yuan in the first three quarters of 2022, up 31.2% year-on-year.

Meanwhile, the company posted 37.4 billion yuan in revenue, up 12.1% year-on-year.

At the end of the reporting period, it had 31.1 billion yuan in total assets and 24.6 billion yuan in total liabilities, with a liability-to-asset ratio of 79%.